The Evidence
Results from studies evaluating more than 6,000 patients demonstrate the impact of the HeartFlow Analysis. The NXT study, which was the basis of our FDA clearance, showed an accuracy of 86% compared to the gold standard of invasive FFR, with high sensitivity and specificity. The PLATFORM study demonstrated an improved patient experience and reduction of costs, without compromising on clinical outcomes. PLATFORM results show that, compared to usual care, a pathway of coronary CT and the HeartFlow Analysis resulted in:

- 83% Reduction of unnecessary angiograms
- 0 Zero adverse clinical events for patients with a cancelled angiogram
- Similar rate of revascularization
- 26% Reduction of cost of care

A Coordinated Effort to Advance Care

Dr. Thomas Phiambolis
Director of Cardiac CT Angiography
Lankenau Heart Institute

“We knew the HeartFlow Analysis was a game changer for our patients, our hospital and the entire industry. It’s fundamentally changing the way we detect and manage coronary artery disease. We’re investing in this pathway and just purchased two new coronary CT scanners to increase the number of patients we can help. Our radiology department, administrative team, referring community and cardiology division are all involved to make this happen. It’s a coordinated effort, but the results are undeniable – we’re keeping healthy patients out of the cath lab. The HeartFlow Analysis gives us the reason we need to make this change, and it’s happening now.”

Built on Clinical Data
Our HeartFlow Analysis is a fundamentally different approach to assessing patients with suspected coronary artery disease. We aim to provide a superior alternative to other testing methods including standard stress testing, such as SPECT and stress echo, that improves outcomes and the patient experience. In validating our approach, we’ve invested decades of scientific research and development, conducted multiple clinical studies, and tested performance in real world settings. This long history of development, including more than 200 peer reviewed publications, has directly led to growing recognition of the HeartFlow Analysis as an important part of a value-based healthcare system.
Recognition and Reimbursement

The healthcare community recognizes the potential of the HeartFlow Analysis and the strength of our clinical data. While transitioning to new technologies is never easy, the barriers to adopting HeartFlow are falling. Now, millions of patients will have access to the technology. Here are some of the recent changes:

$1,450.50 reimbursement for Medicare patients
due to the Centers for Medicare & Medicaid Services (CMS) creating a New Technology Ambulatory Payment Classification (APC) for the HeartFlow Analysis

185 million people in the US
now have access to the HeartFlow Analysis through private commercial payers and Medicare

UK reimbursement from the National Health Service (NHS)
as part of their Innovation and Technology Payment program, following a medical technology guidance issued by NICE recommending the HeartFlow Analysis as the most cost-effective option following a coronary CT